The European Medicines Agency (EMA) has recommended suspending a number of generic medicines approved for use in Europe following an inspection of two sites in India belonging to Micro Therapeutic Research Labs, which were involved in carrying out bioequivalence studies.1,2 The original list of generic medicines recommended for suspension included drugs with marketing authorisation for use in the UK (e.g. tadalafil, naproxen, irbesartan, paracetamol and metformin) from a range of companies (e.g. Milpharm Ltd, Crescent Pharma …